A systematic review and meta-analysis presented at the European Scientific Working Group on Influenza virtual conference on December 7, 2020, confirmed the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.
As announced by Seqirus, the results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.
Benefits Confirmed of Adjuvanted Seasonal Influenza Vaccines
Benefits Confirmed of Adjuvanted Seasonal Influenza Vaccines
A systematic review and meta-analysis presented at the European Scientific Working Group on Influenza virtual conference on December 7, 2020, confirmed the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.
As announced by Seqirus, the results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.
COVID-19 Lockdown Tied to Increased Heavy Drinking
One-third of adults report binge drinking during the pandemic; existing binge drinkers increasing their intake
Flu Shot More Popular Than COVID-19 Vaccine Among Older Adults
58 percent of adults aged 50 to 80 years report being somewhat or very likely to get a COVID-19 vaccine
Rooming-In, Breastfeeding Feasible With Maternal SARS-CoV-2
Rooming-in, breastfeeding can be practiced in women who are able to care for their infants, with low postnatal transmission
CDC Recommends Universal Mask Wearing
Mask wearing is top CDC recommendation to help stop the spread of COVID-19